Its name might call to mind a futuristic French Tickler for the anus, but Fasoracetam is far more tantalizing than that. A nootropic research chemical, Fasoracetam has been used in clinical trials to treat ADHD (Attention Deficit Hyperactivity Disorder). The nootropic was developed by a Japanese pharmaceutical company, Nippon Shinyaku, to manage Alzheimer’s disease. Its assistance in this area comes courtesy of its influence on Choline, Glutamate and GABA neurotransmitters. 

Since its inception in the 1960’s, the drug has been used in a series of non-Alzheimer’s clinical studies. Fasoracetam gained popularity among smart drug users the following decade after. In 2015, BetterYouNetwork.com labelled the nootropic to be a “newer and potent product.

As a nootropic, it’s also known as an anti-depressant and an anxiolytic. A current compound review of Fasoracetam evaluated its antidepressant activity in lab rats. The results bolstered the claim that the drug is capable of altering the brain by creating an influx of GABA receptors in the rat’s cerebral cortex.

Fasoracetam: Drug Studies

Dr. Hakonarson and his team have been investigating Fasoracetam for its potential treatment against ADHD. Repeated references to this study have since been banned by the nootropic community. No one knows why it suddenly came to be the case, but links to Hakonarson’s work are no longer up for viewing.

Nevertheless, there are numerable online resources which point Fasoracetam as a ADHD supplement. Latest reports from the medical community point to Chinese researchers to be in the second trial phase of the drug.  Studies on this racetam vary with one suggesting the nootrppic to be a mGluR 2/3 agonist or metabotropic glutamate receptor. This means Fasoracetam is capable of binding with glutamate to galvanize neurotransmitters, resulting in multiple functions in the central nervous system. Metabotropic glutamate receptors have been shown to effect memory, learning aptitude and perception of pain, among others.

In February of 2016, the FDA accepted Fasoracetam Investigational New Drug Application (IND) for  review. It is unclear, at this time, what their findings of the drug are. Phase III trials for  treatment on ADHD, cognition disorders, and acute depression in the United States have been discontinued.

Regardless of where medical experts and Food and Drug Administration stand, the nootropic community have embraced the drug for its health benefits. Some insist Fasoracetam is capable of protecting the brain against amnesia, short-term memory while minimizing anxiety and symptoms associated with Alzheimer’s. It’s also capable of treating narcolepsy, insomnia, and improving mood.

Despite positive public response to Fasoracetam, there have yet been a sufficient number of studies done in determining the drug’s safety. Reports of allergic reactions, vomiting, and liver/kidney function changes have been widely reported. These side effects only transpire when a user takes the drug in in excess of the recommended dosage(s)

Headaches are likewise common among casual users of the drug. Due to largely untested nature of the drug and some of its allergic components, it is strongly recommended for pregnant or lactating mothers to abstain taking it.

A Favorite Stack

Fasoracetam has earned itself a rep as a stacker’s wet dream. It performs well in conjunction with other supplements. It pairs well with Alpha GPC (for cognitive enhancement), Fish Oil, Tianeptine (to enhance mood), Coluracetam (to enhance mood), Phenibut and Magnesium (to relieve anxiety), Aniracetam (for longer memory retention and mental stamina), and Buspirone (part of the Ultimate Health Stack) and a host of other stacks.

Recommended Dosage

Fasocracetam has the usual contraindications of all drugs in the Racetam family. The initial recommended dosage of Fasoracetam is 10 mg. It’s recommended not to go beyond 50 mg to avoid side effects. Fasoracetam can be purchased from any number of fine retailers, including here.

Erica Silva on Twitter
Erica Silva
Senior Editor
Erica Silva is a blogger by choice. She loves to discover the world around her. She likes to share her discoveries, experiences and express herself through her blogs. Currently, she is associated with DementiaTalk Team.

Comments are closed here.